(Photo By: Hadassah)
By: Abigail Klein Leichman - May 12, 2021
A team from Hadassah Hebrew University Medical Center in Jerusalem is now in Argentina sharing its experience in dealing with the Covid-19 pandemic, at the invitation of the Argentinian government.
The team also is exploring the possibility of starting a Phase III trial of the BriLife Covid-19 vaccine in Argentina. This vaccine candidate was developed jointly by Hadassah and the Israel Institute for Biological Research.
On Tuesday, ISRAEL21c spoke with delegation head Prof. Yoram Weiss, director of Hadassah’s Ein Kerem campus, where approximately 4,500 Covid-19 patients were treated – more than any other Israeli hospital.
Read More: Israel21c